Valuation: Evogene Ltd.

Market Cap 5.28M 0 4.59M 4.27M 3.92M 7.41M 504M 7.52M 50.37M 19.77M 251M 19.83M 19.4M 842M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 5.28M 0 4.59M 4.27M 3.92M 7.41M 504M 7.52M 50.37M 19.77M 251M 19.83M 19.4M 842M EV / Sales 2026 *
3.56x
EV / Sales 2027 * 2.03x
Free-Float
82.39%
Yield 2026 *
-
Yield 2027 * -
1 day-6.69%
1 week-14.95%
Current month-6.69%
1 month+10.59%
3 months-36.19%
6 months-53.73%
Current year-51.73%
1 week 145.1
Extreme 145.1
164
1 month 122.7
Extreme 122.7
194.1
Current year 115.1
Extreme 115.1
410
1 year 115.1
Extreme 115.1
478.7
3 years 115.1
Extreme 115.1
3,700
5 years 115.1
Extreme 115.1
10,430
10 years 115.1
Extreme 115.1
33,500
Manager TitleAgeSince
Chief Executive Officer 60 01/12/2004
Corporate Officer/Principal - -
Corporate Officer/Principal - 01/01/2022
Director TitleAgeSince
Director/Board Member 60 -
Director/Board Member 77 03/06/2010
Chairman 60 01/06/2021
Date Insider Type Main position Quantity % Market Cap.
18/3/26 Other

Executive/Senior Manager

40,000 0.4588%
Change 5-day change 1-year change 3-year change Capi.($)
-6.69%-14.95%-64.23%-96.15% 5.28M
+1.00%+1.47%+0.35%+15.84% 48.53B
-2.41%-0.90%+411.96%+472.09% 39.87B
-1.16%+12.96%+28.81%+7.27% 38.68B
-1.88%-3.03%+5.69%+66.52% 35.13B
-1.74%+5.12%+14.44%+44.64% 29.79B
-0.21%-4.04%+36.40%+126.06% 16.11B
-2.85%-3.92% - - 16.08B
+0.85%+2.63%+3.22%+16.64% 13.61B
-1.19%-1.32%-1.73%-34.97% 12.62B
Average -1.46%-0.09%+48.32%+68.66% 25.04B
Weighted average by Cap. -0.80%+2.03%+80.20%+108.19%

Financials

2026 *2027 *
Net sales 1.48M 0 1.29M 1.2M 1.1M 2.08M 142M 2.11M 14.15M 5.55M 70.53M 5.57M 5.45M 236M 2.6M 0 2.26M 2.1M 1.93M 3.65M 248M 3.7M 24.8M 9.73M 124M 9.76M 9.55M 414M
Net income -16.69M -0 -14.51M -13.5M -12.4M -23.41M -1.59B -23.77M -159M -62.46M -793M -62.67M -61.29M -2.66B -13.92M -0 -12.1M -11.26M -10.34M -19.52M -1.33B -19.82M -133M -52.09M -661M -52.26M -51.11M -2.22B
Net Debt - -
Logo Evogene Ltd.
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Employees
52
Date Price Change Volume
03/08/26 ILA 145.10 -6.69% 60,455
31/07/26 ILA 155.50 +0.91% 280
30/07/26 ILA 154.10 -2.78% 37,943
29/07/26 ILA 158.50 -1.00% 50,045
28/07/26 ILA 160.10 -6.15% 80,169

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVGN Stock